Latigo Biotherapeutics, Inc. — Form 10-Q
Filed September 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
This is a routine quarterly report (10-Q) for Latigo Biotherapeutics for the period ending June 30, 2026, filed September 3, 2026. The filing consists of standard disclosure documents (certification exhibits EX-31.1, EX-31.2, EX-32.1) and XBRL data. No specific financial results, material transactions, personnel changes, litigation, or operational events are provided in the document metadata or header text.
Why this rating
Routine quarterly SEC filing with no disclosed material events; standard administrative disclosure only.
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.